Mark Gannott
Health Economics · Capital
“Every number is either cited or red-flagged.”
Bio
Mark Gannott is Chief Financial Officer of Suncoast Ventures Fund II, where he leads fund finance, valuation, portfolio analytics, and investment underwriting across healthcare and life sciences. He helps evaluate how scientific, clinical, reimbursement, and commercial risk translate into enterprise value over successive financing rounds.
He is an Adjunct Fellow at the NICM Health Research Institute at Western Sydney University, where he leads health-economic research across women's health and clinical decision support. His work includes national cost-of-illness studies, budget-impact models, and translational research supporting healthcare implementation, policy, and capital formation.
Previously, he worked across neuroscience, neuroeconomics, mental health research, cannabis genomics, psychedelic medicine, clinical decision support, and health economics. His experience spans academic research, translational medicine, venture-backed healthcare companies, and public policy, with work focused on helping complex healthcare innovations become clinically, economically, and commercially viable.
At Suncoast, he brings that interdisciplinary perspective to investment decisions, integrating scientific evidence, health economics, and commercial strategy into a single framework for evaluating risk and value creation.
Backstory
I came into venture through health economics, not finance-for-its-own-sake. My work started with the questions payers and policymakers actually ask — what does this cost, who bears it, and does the evidence hold — and that discipline is what I bring to the fund.
I've built published, nationwide cost-of-illness models (including endometriosis in New Zealand) and peer-reviewed methodology for diagnostic-delay attribution. The through-line is the same: rigor over narrative, and no unsourced numbers.
At Suncoast I'm the CFO and the person pressure-testing the economics — the risk frameworks and analytical infrastructure behind the fund's performance — and a fractional CFO across several portfolio companies.
What I'm looking for
Companies with a real economic case — a defensible cost-offset or value story a payer would actually underwrite, not a slide.
Founders who can separate what they know from what they're guessing, and who treat evidence as a moat.